Hepatitis C: a patient's journey from a psychiatrist's perspective
Authors:
- Vellingiri Raja BadrakalimuthuVBVellingiri Raja Badrakalimuthu
- Daphne RumballDRDaphne Rumball
- Amit ChawlaACAmit Chawla
- 1 September 2011
- journal article
- Published by Cambridge University Press (CUP) in Advances in Psychiatric Treatment
- Vol. 17 (5) , 340-349
Abstract
Summary: There is an increasing prevalence of hepatitis C, particularly among intravenous drug users. Estimates of infection with the hepatitis C virus (HCV) in patients with severe mental illness in the USA have ranged from 8.5% to 19.6%. Alcohol use and misuse is the single biggest contributory factor to the development of fatal liver disease in people with hepatitis C. Neuropsychiatric symptoms are present in HCV infection, independent of any treatment. Despite such alarming observations, the success rate of antiviral treatment in chronic hepatitis C has improved considerably in recent years. This article explores psychiatrists' involvement in advocating for treatment inclusion, assessing patients' capacity to make treatment-related decisions and supporting the medical team in managing the complex journey a patient undertakes from being at high risk to receiving treatment for neuropsychiatric symptoms.Keywords
This publication has 49 references indexed in Scilit:
- Management of Hepatitis C Disease Among VA Patients With Schizophrenia and Substance Use DisordersPsychiatric Services, 2006
- Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis CJournal of Hepatology, 2005
- Mania During Treatment of Chronic Hepatitis C With Pegylated Interferon and RibavirinAmerican Journal of Psychiatry, 2004
- Hepatitis C virus infection among noninjecting drug users in New York CityJournal of Medical Virology, 2003
- Prevalence of Hepatitis C Among Psychiatric Patients in the Public SectorAmerican Journal of Psychiatry, 2003
- Neurobehavioral Effects of Interferon-α in Cancer Patients Phenomenology and Paroxetine Responsiveness of Symptom DimensionsNeuropsychopharmacology, 2002
- Paroxetine for the Prevention of Depression Induced by High-Dose Interferon AlfaNew England Journal of Medicine, 2001
- Epidemiology of hepatitis CHepatology, 1997
- Side effects of high-dose interferon therapy for chronic hepatitis CJournal of Hepatology, 1996
- The CES-D ScaleApplied Psychological Measurement, 1977